(Q38133017)

29 August 2017

title

Clinical aspects of autoimmune rheumatic diseases (English)

1 reference

29 August 2017

Fiona Goldblatt

1

1 reference

29 August 2017

Sean G O'Neill

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

382

1 reference

29 August 2017

issue

9894

1 reference

29 August 2017

page(s)

797-808

1 reference

Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Long-term outcome of mothers of children with isolated heart block in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic scl

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Development of classification and response criteria for rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

1 reference

7 January 2021

Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Autoantibodies as predictive tools in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Validation of potential classification criteria for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Polymyositis and dermatomyositis (first of two parts)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Polymyositis and dermatomyositis (second of two parts)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Utilizing registries in systemic lupus erythematosus clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

The genetics of lupus: a functional perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Immunopathogenic mechanisms of systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Incidence and prevalence of systemic sclerosis: a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Genetics of systemic sclerosis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Unraveling the genetic component of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Occupational silica exposure as a risk factor for scleroderma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Meta-analysis of systemic sclerosis and exposure to solvents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Polymyositis: an overdiagnosed entity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Epidemiology of ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Epidemiology of large-vessel vasculidities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

The immune system in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

The bimodal mortality pattern of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Mortality in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Cardiovascular disease in systemic sclerosis--an emerging association?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Heart structure and function in patients with generalized autoimmune diseases: echocardiography with tissue Doppler study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Accelerated atherosclerosis in autoimmune rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Non-Hodgkin's lymphoma in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

An international cohort study of cancer in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Interstitial lung disease in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Risk factors for lung cancer in patients with scleroderma: a nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Determinants of morbidity and mortality of systemic sclerosis in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Changes in causes of death in systemic sclerosis, 1972-2002

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Interstitial lung disease in systemic sclerosis: a simple staging system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961499-3

7 January 2021

10.1016/S0140-6736(13)61499-3

Identifiers

DOI

1 reference

29 August 2017

1 reference